fosfomycin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 1243 23155-02-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fosfomycin trometamol
  • fosfomycin
  • fosfomycin tromethamine
An antibiotic produced by Streptomyces fradiae.
  • Molecular weight: 138.06
  • Formula: C3H7O4P
  • CLOGP: -0.03
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 70.06
  • ALOGS: -0.47
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
8 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 82 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 192.90 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 31 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.32 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 1996 FDA ZAMBON SPA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 226.80 26.54 51 7323 1856 63479792
Palmoplantar keratoderma 224.20 26.54 51 7323 1956 63479692
Pruritus genital 210.03 26.54 51 7323 2603 63479045
Sleep terror 209.53 26.54 51 7323 2629 63479019
Atrial tachycardia 190.97 26.54 52 7322 4188 63477460
Carotid artery occlusion 181.18 26.54 51 7323 4643 63477005
Tension headache 176.15 26.54 51 7323 5135 63476513
Anosmia 170.45 26.54 53 7321 6807 63474841
Facial pain 148.01 26.54 53 7321 10508 63471140
Immunisation 136.93 26.54 31 7343 1162 63480486
Pain of skin 135.69 26.54 51 7323 11583 63470065
Subarachnoid haemorrhage 125.53 26.54 51 7323 14232 63467416
Ventricular tachycardia 115.31 26.54 53 7321 19926 63461722
Vasculitis 113.60 26.54 51 7323 18158 63463490
Eye pruritus 112.38 26.54 51 7323 18620 63463028
Muscle twitching 109.84 26.54 51 7323 19617 63462031
Blindness 108.09 26.54 52 7322 21647 63460001
Diplopia 100.74 26.54 51 7323 23677 63457971
Lip swelling 95.90 26.54 54 7320 31009 63450639
Hallucination 87.98 26.54 63 7311 54754 63426894
Transient ischaemic attack 83.63 26.54 53 7321 37700 63443948
Tinnitus 78.87 26.54 50 7324 35578 63446070
Disturbance in attention 78.13 26.54 51 7323 38138 63443510
Angioedema 72.12 26.54 53 7321 47912 63433736
Dry skin 70.46 26.54 56 7318 56831 63424817
Rash papular 67.36 26.54 34 7340 15668 63465980
Cognitive disorder 67.11 26.54 54 7320 55761 63425887
Amnesia 65.18 26.54 53 7321 55532 63426116
Intentional product misuse 60.94 26.54 53 7321 60864 63420784
Heart rate increased 54.91 26.54 61 7313 94177 63387471
COVID-19 52.25 26.54 65 7309 113038 63368610
Tachycardia 51.57 26.54 66 7308 118090 63363558
Migraine 48.71 26.54 60 7314 103286 63378362
Blood glucose increased 48.42 26.54 54 7320 83702 63397946
Feeling abnormal 48.38 26.54 72 7302 148320 63333328
Drug reaction with eosinophilia and systemic symptoms 47.74 26.54 36 7338 33800 63447848
Visual impairment 44.67 26.54 52 7322 84394 63397254
Dehydration 42.65 26.54 74 7300 173280 63308368
Hyperhidrosis 42.03 26.54 57 7317 107779 63373869
Myocardial infarction 39.23 26.54 53 7321 99840 63381808
Palpitations 38.59 26.54 56 7318 112714 63368934
Muscular weakness 37.92 26.54 58 7316 122295 63359353
Memory impairment 34.54 26.54 51 7323 104207 63377441
Pericarditis 33.43 26.54 57 7317 131522 63350126
Stevens-Johnson syndrome 29.67 26.54 24 7350 24926 63456722
Respiratory alkalosis 28.45 26.54 11 7363 2690 63478958
Malaise 28.26 26.54 109 7265 415845 63065803
Pruritus 28.14 26.54 99 7275 361354 63120294
Umbilical cord around neck 27.32 26.54 6 7368 195 63481453
Mechanical urticaria 26.95 26.54 7 7367 469 63481179
Anxiety 26.73 26.54 70 7304 217471 63264177

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 295.85 54.53 66 6034 1522 34949309
Palmoplantar keratoderma 276.99 54.53 65 6035 1888 34948943
Pruritus genital 264.04 54.53 64 6036 2140 34948691
Sleep terror 260.83 54.53 64 6036 2254 34948577
Tension headache 248.37 54.53 65 6035 2977 34947854
Atrial tachycardia 241.37 54.53 66 6034 3579 34947252
Facial pain 235.69 54.53 65 6035 3639 34947192
Carotid artery occlusion 235.12 54.53 65 6035 3672 34947159
Anosmia 234.91 54.53 66 6034 3958 34946873
Immunisation 201.88 54.53 45 6055 1032 34949799
Pain of skin 199.47 54.53 64 6036 6045 34944786
Eye pruritus 198.45 54.53 67 6033 7422 34943409
Pericarditis 169.59 54.53 67 6033 11578 34939253
Vasculitis 168.04 54.53 66 6034 11230 34939601
Muscle twitching 166.77 54.53 64 6036 10234 34940597
Lip swelling 164.83 54.53 72 6028 16008 34934823
Subarachnoid haemorrhage 160.87 54.53 66 6034 12569 34938262
Blindness 146.79 54.53 65 6035 14921 34935910
Migraine 140.30 54.53 66 6034 17412 34933419
Diplopia 136.42 54.53 64 6036 16779 34934052
Tinnitus 128.53 54.53 65 6035 20053 34930778
Rash papular 128.47 54.53 53 6047 10225 34940606
Disturbance in attention 126.56 54.53 70 6030 25875 34924956
Pathogen resistance 125.70 54.53 51 6049 9431 34941400
Dry skin 119.53 54.53 72 6028 31215 34919616
Amnesia 114.24 54.53 66 6034 26497 34924334
Alopecia 114.11 54.53 64 6036 24291 34926540
Ventricular tachycardia 111.54 54.53 65 6035 26514 34924317
Transient ischaemic attack 109.24 54.53 65 6035 27548 34923283
Cognitive disorder 106.94 54.53 65 6035 28628 34922203
Visual impairment 100.90 54.53 68 6032 35734 34915097
Angioedema 93.57 54.53 66 6034 37308 34913523
Palpitations 89.56 54.53 66 6034 39920 34910911
Memory impairment 82.69 54.53 65 6035 43253 34907578
Intentional product misuse 79.73 54.53 65 6035 45546 34905285
Hallucination 76.87 54.53 67 6033 51431 34899400
Heart rate increased 76.74 54.53 64 6036 46279 34904552
COVID-19 67.27 54.53 75 6025 77475 34873356
Abdominal discomfort 64.55 54.53 65 6035 59770 34891061
Feeling abnormal 63.33 54.53 66 6034 63169 34887662
Blood glucose increased 58.66 54.53 65 6035 66653 34884178
Muscular weakness 57.28 54.53 67 6033 72830 34878001

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 501.39 28.82 114 12461 3187 79728626
Palmoplantar keratoderma 482.68 28.82 113 12462 3603 79728210
Sleep terror 457.14 28.82 112 12463 4346 79727467
Pruritus genital 456.44 28.82 112 12463 4374 79727439
Atrial tachycardia 418.78 28.82 115 12460 7018 79724795
Tension headache 408.31 28.82 113 12462 7098 79724715
Carotid artery occlusion 401.75 28.82 113 12462 7534 79724279
Anosmia 398.75 28.82 116 12459 8728 79723085
Facial pain 356.47 28.82 115 12460 12235 79719578
Pain of skin 325.76 28.82 112 12463 14501 79717312
Immunisation 324.52 28.82 74 12501 2093 79729720
Eye pruritus 299.09 28.82 115 12460 20455 79711358
Subarachnoid haemorrhage 276.35 28.82 114 12461 24351 79707462
Vasculitis 273.52 28.82 114 12461 24988 79706825
Muscle twitching 268.27 28.82 112 12463 24652 79707161
Blindness 260.03 28.82 114 12461 28269 79703544
Lip swelling 243.63 28.82 122 12453 40789 79691024
Diplopia 235.90 28.82 112 12463 33354 79698459
Ventricular tachycardia 220.51 28.82 115 12460 41820 79689993
Tinnitus 206.11 28.82 112 12463 44221 79687592
Disturbance in attention 205.21 28.82 117 12458 50684 79681129
Transient ischaemic attack 195.93 28.82 115 12460 52580 79679233
Dry skin 190.78 28.82 124 12451 67871 79663942
Rash papular 181.37 28.82 82 12493 21834 79709979
Amnesia 179.37 28.82 116 12459 62941 79668872
Hallucination 169.26 28.82 126 12449 85619 79646194
Cognitive disorder 168.45 28.82 116 12459 69810 79662003
Angioedema 157.41 28.82 115 12460 75920 79655893
Migraine 155.99 28.82 121 12454 87372 79644441
Visual impairment 139.93 28.82 116 12459 92015 79639798
Pericarditis 137.42 28.82 121 12454 104115 79627698
Intentional product misuse 134.60 28.82 115 12460 95050 79636763
Pathogen resistance 126.10 28.82 56 12519 14286 79717527
Heart rate increased 124.09 28.82 122 12453 120602 79611211
COVID-19 120.45 28.82 136 12439 157538 79574275
Blood glucose increased 117.81 28.82 116 12459 114859 79616954
Memory impairment 114.98 28.82 113 12462 111621 79620192
Palpitations 112.00 28.82 118 12457 126492 79605321
Feeling abnormal 104.41 28.82 127 12448 159072 79572741
Tachycardia 97.89 28.82 130 12445 177638 79554175
Muscular weakness 95.43 28.82 122 12453 160607 79571206
Hyperhidrosis 88.37 28.82 114 12461 151378 79580435
Myocardial infarction 75.40 28.82 117 12458 184012 79547801
Dehydration 67.96 28.82 132 12443 248055 79483758
Drug resistance 63.70 28.82 53 12522 42160 79689653
Alopecia 60.84 28.82 121 12454 231234 79500579
Chest pain 59.61 28.82 135 12440 282169 79449644
Insomnia 58.30 28.82 123 12452 245047 79486766
Abdominal pain upper 57.58 28.82 116 12459 223703 79508110
Anxiety 57.16 28.82 123 12452 248389 79483424
Pruritus 53.70 28.82 160 12415 394488 79337325
Intentional product use issue 53.17 28.82 90 12485 152022 79579791
Peripheral swelling 51.51 28.82 124 12451 269493 79462320
Back pain 50.90 28.82 133 12442 304047 79427766
Abdominal discomfort 50.81 28.82 118 12457 250609 79481204
Malaise 49.09 28.82 179 12396 489690 79242123
Death 41.12 28.82 19 12556 566495 79165318
Adverse drug reaction 38.71 28.82 50 12525 66342 79665471
Toxicity to various agents 32.37 28.82 13 12562 421527 79310286
Conductive deafness 29.44 28.82 7 12568 238 79731575
Drug hypersensitivity 28.84 28.82 6 12569 298910 79432903

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XX01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Other antibacterials
ATC S02AA17 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:78379 EC 2.5.1.7 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urinary tract infectious disease indication 68566005
Escherichia coli urinary tract infection indication 301011002
Enterococcus Urinary Tract Infection indication
Kidney disease contraindication 90708001 DOID:557
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.54 acidic
pKa2 5.59 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
UDP-N-acetylglucosamine 1-carboxyvinyltransferase Enzyme INHIBITOR IC50 7 CHEMBL CHEMBL
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 1 Enzyme WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 2 Enzyme WOMBAT-PK
UDP-N-acetylglucosamine 1-carboxyvinyltransferase Enzyme IC50 4.98 CHEMBL

External reference:

IDSource
4024047 VUID
N0000022052 NUI
D00925 KEGG_DRUG
78964-85-9 SECONDARY_CAS_RN
4021007 VANDF
4024047 VANDF
C0016610 UMLSCUI
CHEBI:62419 CHEBI
FCN PDB_CHEM_ID
CHEMBL1757 ChEMBL_ID
DB00828 DRUGBANK_ID
CHEMBL1200331 ChEMBL_ID
D005578 MESH_DESCRIPTOR_UI
446987 PUBCHEM_CID
3014 INN_ID
10813 IUPHAR_LIGAND_ID
2N81MY12TE UNII
142135 RXNORM
29490 MMSL
340066 MMSL
4765 MMSL
d04106 MMSL
004467 NDDF
004468 NDDF
108720006 SNOMEDCT_US
108721005 SNOMEDCT_US
372534005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Monurol HUMAN PRESCRIPTION DRUG LABEL 1 0456-4300 POWDER 3 g ORAL NDA 23 sections
Monurol HUMAN PRESCRIPTION DRUG LABEL 1 0456-4300 POWDER 3 g ORAL NDA 23 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5826 POWDER 3 g ORAL ANDA 20 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5826 POWDER 3 g ORAL ANDA 20 sections
Fosfomycin Tromethamine Human Prescription Drug Label 1 50090-6130 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
Fosfomycin Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 63629-9470 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
Fosfomycin Tromethamine Human Prescription Drug Label 1 67877-749 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
Fosfomycin Tromethamine Human Prescription Drug Label 1 67877-749 GRANULE, FOR SOLUTION 3 g ORAL ANDA 21 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 69097-579 GRANULE, FOR SOLUTION 3 g ORAL ANDA 18 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 70700-268 POWDER 3 g ORAL ANDA 20 sections
FOSFOMYCIN TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 70700-268 POWDER 3 g ORAL ANDA 20 sections
Fosfomycin Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 82036-4274 POWDER 3 g ORAL NDA authorized generic 22 sections
Fosfomycin Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 82036-4274 POWDER 3 g ORAL NDA authorized generic 22 sections